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ABSTRACT
Introduction: This study examined the use of
anti-tumor necrosis factor (anti-TNF)
monotherapy, adherence with non-biologic
disease-modifying anti-rheumatic drugs
(nbDMARDs) in patients receiving a
combination of anti-TNF therapies and
nbDMARDs, and the impact of nbDMARD
adherence on anti-TNF persistence among
patients with rheumatoid arthritis (RA).
Methods: Patients with RA (aged C18 years)
from a US commercial health plan with claims
for anti-TNFs (2006–2010) were defined as
either biologic-naive or -exposed anti-TNF
initiators based on previous nbDMARD use.
Adherence to nbDMARDs and anti-TNF
persistence were estimated. Cox regression
estimated the association between nbDMARD
adherence and anti-TNF persistence.
Results: Among 9764 patients identified (mean
age 50.2 years; 78% female), 55% of
biologic-naive patients and 49% of previously
exposed patients initiated any combination
therapy during follow-up. Among
biologic-naive combination therapy patients,
53% adhered to nbDMARD therapy \80% of
the time while receiving anti-TNF therapies;
33% had\60% adherence. Compared with the
most adherent patients, patients adherent to
nbDMARDs 20% to 79% of the time were 30%
to 20% more likely to discontinue their
anti-TNF therapy in the period [90 days after
starting the anti-TNF therapy. This relationship
was not observed for patients with nbDMARD
adherence of \20% (who were less likely to
discontinue their anti-TNF therapy during the
first 90 days of treatment).
Conclusion: Almost one-third of patients with
RA receiving anti-TNF therapy received it as
pure monotherapy. About one-third of
combination therapy recipients had \60%
adherence to nbDMARDs. Higher nbDMARD
adherence may be associated with better
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anti-TNF persistence after an initial treatment
period.
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INTRODUCTION
Rheumatoid arthritis (RA) affects upwards of an
estimated 1.3 million persons in the United
States over the age of 18 years, with a growing
prevalence among those over the age of 60 [1,
2]. The clinical and economic burden of RA is
significant [3], whether measured by the impact
on quality of life, direct treatment costs, or
indirect costs in the form of productivity loss [4,
5]. Successful treatment of RA can improve
patients’ quality of life [5] and reduce costs
associated with loss of productivity [6].
Guidelines provided by the American College
of Rheumatology call for early, aggressive
treatment of RA to slow the progression of the
disease [7]. Typically, non-biologic
disease-modifying anti-rheumatic drugs
(nbDMARDs) are the first line of treatment.
Biologics, including anti-tumor necrosis factor
drugs (anti-TNFs), are often added to the
nbDMARD for patients who do not experience
improvement after nbDMARD treatment.
Studies have shown a better response to
anti-TNFs when used in combination with
nbDMARDs than when used as monotherapies
[8, 9]. Adherence to nbDMARDs prescribed in
combination with anti-TNFs may impact the
benefit obtained with the use of these biologic
therapies. The objectives of this study were to
examine (1) the use of anti-TNF therapies as
monotherapy, (2) adherence with concomitant
nbDMARDs in patients receiving a combination
of anti-TNFs and nbDMARDs, and (3) the
impact of concomitant nbDMARD adherence
on anti-TNF persistence in a real-world setting
among commercially insured patients with RA.
METHODS
Study Design
A retrospective claims-based analysis using data
from a US managed care plan was conducted.
Patients were followed from anti-TNF initiation
to discontinuation of that specific anti-TNF or
disenrollment from the managed care plan.
Data Sources
Patients were identified from a large US
commercial health plan (Optum Research
Database) that represents *14 million
members annually. The administrative claims
data included medical claims, pharmacy claims,
eligibility information, and linked mortality
data from the Social Security Administration’s
death master files. The individuals covered by
this health plan are geographically diverse
across the US, with greatest representation in
the South and Midwest US census regions.
Patients included in the study were insured in
plans that provided coverage for professional
(e.g., physician), facility (e.g., hospital), and
outpatient prescription medication services.
Medical (professional, facility) claims included
International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM)
diagnosis codes, procedures recorded with
ICD-9-CM procedure codes, Current
Procedural Terminology, or Healthcare
Common Procedure Coding System codes, site
of service codes, and revenue codes (for
facilities). Outpatient pharmacy claims
provided National Drug Codes for dispensed
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medications, quantity dispensed, drug strength,
and days’ supply. This study was conducted in
compliance with the Health Insurance
Portability and Accountability Act Privacy Rule.
Patient Selection
Patients aged 18 years or older who were
identified as having at least one medical claim
for RA (ICD-9-CM diagnosis code of 714.xx)
were included if they initiated anti-TNF
medications during the patient identification
period of January 1, 2006 through December 31,
2010. Patients initiating multiple biologics
during the study period were eligible for more
than one medication-related cohort, and the
date of the first claim for each biologic therapy
represented the index date for that therapy.
Only those with continuous enrollment for
6 months prior to the index date and
12 months after were included. Anti-TNF
medications included adalimumab,
certolizumab pegol, etanercept, golimumab,
and infliximab, while nbDMARDs included
auranofin, aurothioglucose, azathioprine,
chloroquine, cyclophosphamide,
D-penicillamine, gold sodium thiomalate,
cyclosporine, hydroxychloroquine,
leflunomide, methotrexate (MTX), and
sulfasalazine. Patients with more than one
biologic on a particular index date or with
evidence of prior use of the index medication
were excluded from analysis of that medication.
Also excluded were patients with conditions
other than RA that were labeled indications for
the biologic medications.
Study Measures
Patients were classified into several defined
groups based on their treatment patterns with
nbDMARD and anti-TNF medications, resulting
in 3 main classifications. The first designation
was based on prior biologic exposure.
‘Biologic-exposed’ patients were those who
had filled a different biologic prescription
during the 6-month baseline period prior to
the index date, whereas ‘biologic-naive’ patients
were those who did not.
The second classification placed patients into
either combination therapy or monotherapy
groups. ‘Combination therapy initiators’ were
those who had filled prescriptions or
administrations for nbDMARDs within 30 days
after their index date, or who had filled a
prescription within 30 days prior to the index
date with a medication supply that covered the
period through at least 30 days after the index
date. ‘Monotherapy initiators’ were patients
who initiated anti-TNF therapy and who did
not meet the definition for combination
therapy initiators. Third, we assessed what
proportion of patients stayed on monotherapy
for the entire duration of their anti-TNF
treatment. ‘Pure monotherapy’ referred to
treatment with anti-TNF monotherapy that
never included an nbDMARD during anti-TNF
follow-up, whereas patients with nbDMARD
therapy at any time during anti-TNF follow-up
were referred to as the ‘any combination
therapy’ group.
The primary study outcomes included
adherence with nbDMARDs and persistence
with anti-TNF medications. Adherence to
nbDMARDs was estimated from the
proportion of days covered. Specifically, it
represents the percentage of days that patients
received any nbDMARD while they were
receiving the anti-TNF therapy. Perfect (100%)
adherence indicates that patients possessed
some nbDMARD 100% of the time during
their anti-TNF follow-up based on filled
prescriptions or administrations. In addition to
adherence with any nbDMARDs, adherence to
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MTX was assessed separately. Anti-TNF
persistence represented the time from the start
of use until discontinuation of that anti-TNF
therapy (a gap in supply of 60 days or a switch
to a different biologic) or censoring due to
disenrollment or the end of the study. For
medications identified in pharmacy claims, the
last date of supply was identified based on the
days’ supply on all fills for that medication; for
medications administered in a physician office
or inpatient setting, the days’ supply was
imputed for the last administration based on
dosing intervals described on medication labels.
Patient characteristics included age, sex, and
geographic location. Clinical characteristics
were established during the 6-month baseline
period before the index date.
Statistical Analysis
All study variables, including baseline and
outcome measures, were analyzed
descriptively. Numbers and percentages were
calculated for dichotomous and polychotomous
variables. Means, standard deviations, and
percentiles were calculated for continuous
variables. Descriptive analyses are presented
separately for biologic-naive and previously
exposed patients for each index anti-TNF.
When comparing groups, the appropriate
statistical test (e.g., t test, Mann–Whitney
U test, v2 test) was used based on the
distribution of the variable(s) of interest.
Bivariate comparisons of baseline
characteristics and outcome measures are
presented. Multivariate Cox proportional
hazards models were used to assess the
association between nbDMARD adherence and
anti-TNF persistence (i.e., time to
discontinuation) for each patient’s first
observed anti-TNF therapy, among patients
who initiated their anti-TNF therapy as
combination therapy with an nbDMARD. The
Cox models included nbDMARD adherence as a
time-dependent factor by measuring adherence
at each instance of anti-TNF discontinuation
and treating the non-discontinuing patients at
that time point as controls. Adherence was
modeled as an ordinal variable in 20%
increments, and the reference group consisted
of patients with[80% adherence. In addition,
based on initial review of the results, the model
included interaction terms for the nbDMARD
adherence with the time from initiation of the
anti-TNF therapy, as the initial descriptive
results suggested that the effect of nbDMARD
adherence on anti-TNF discontinuation varied
by time. Time from anti-TNF initiation was
dichotomized as B90 days and [90 days from
initiation; the hazard ratios for the effect of
nbDMARD adherence are presented separately
for each of these time periods. These models
were also adjusted for line of therapy, specific
anti-TNF medication, age, sex, Charlson
comorbidity score, and baseline use of
injectable or oral corticosteroids. SAS version
9.2 (SAS Institute Inc, Cary, NC) was used for
constructing the analytic data set and for
statistical analyses.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Sample Selection and Baseline
Characteristics
After applying all of the inclusion and exclusion
criteria, the final study population included a
total of 9764 patients, with 7074 patients
classified as biologic naive and 2690 classified
as previously biologic exposed (Fig. 1). The
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mean age of the study population was
*50 years and study patients were
predominately female (Table 1). More than
half of all patients were located geographically
in the South. Corticosteroids were used by 62%
of patients with first-line monotherapy and
70% of patients with first-line combination
therapy, although the proportion of days
covered was low (17% and 22% of days for
monotherapy and combination therapy,
respectively).
Outcomes
Monotherapy Initiators vs. Combination
Therapy Initiators
Among all patients initiating anti-TNFs, 45% of
biologic-naive patients and 51% of
biologic-exposed patients initiated an anti-TNF
agent as a monotherapy; the remaining patients
initiated anti-TNFs as part of combination
therapy (Fig. 2). This was similar among the
individual anti-TNF agents: 31% to 52% of
biologic-naive patients and 46% to 55% of
biologic-exposed patients were monotherapy
initiators.
Pure Monotherapy vs. Any Combination
Therapy Users During anti-TNF follow-up,
27% of all patients in the biologic-naive group
and 31% of all patients in the biologic-exposed
group received anti-TNF therapy as pure
monotherapy; the remaining patients received
an nbDMARD during follow-up (Fig. 2). When
stratified by the individual anti-TNF agents, the
percentage of patients identified as pure
monotherapy ranged from 18% to 32% for the
biologic-naive group and 23% to 35% for those
previously exposed to biologics. 42% of
biologic-naive patients on pure monotherapy
and 89% of biologic-naive patients on
combination therapy were administered an
nbDMARD during the 6-month baseline
period prior to initiating anti-TNF medication
(Table 1); for patients previously exposed to
biologics, those values were 32% and 89%,
respectively.
Adherence to nbDMARDs Among Any
Combination Therapy Users Among
biologic-naive combination therapy patients,
53% of patients adhered to nbDMARD therapy
\80% of the time while receiving anti-TNFs
(proportion of days covered\80%); 33% of the
Fig. 1 Patient selection. For each qualifying line
subsequent to the ﬁrst line, patients can appear multiple
times in this data set (i.e., multiple records per patient).
ABT abatacept, anti-TNFs anti-tumor necrosis factor
drugs, IFX inﬂiximab, RTX rituximab, TOC tocilizumab
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patients had\60% adherence (Fig. 3a). Among
biologic-naive patients who received anti-TNF
combination therapy with MTX, 58% had
\80% adherence to MTX and 35% had \60%
adherence to MTX while receiving the anti-TNF
(Fig. 3b). Similar results were observed for
anti-TNF patients previously exposed to
biologics (Fig. 3c, d).
Association Between Concomitant nbDMARD
Adherence and Anti-TNF Persistence Average
persistence with anti-TNF treatment was lower
for patients receiving pure monotherapy
(333 days for biologic-naive and 283 days for
previously exposed patients) than for
combination therapy users (522 days for
biologic-naive and 426 days for previously
exposed patients). Overall, we did not find a
significant association between adherence to
concomitant nbDMARDs and anti-TNF
persistence. It is known that while some
biologic users may not respond right from
the outset (primary non-response), a
proportion of patients may fail to maintain
their initial response (secondary
non-response). We therefore examined the
association within subgroups stratified by
duration of follow-up (B90 days and
[90 days) to determine whether nbDMARD
adherence would have an impact within those
time frames on primary or secondary
non-response, respectively (Fig. 4). Within the
first 90 days there was no statistically
significant difference in anti-TNF persistence
for patients with different levels of nbDMARD
adherence, with the exception of patients with
adherence of 20% to 39%, who were
significantly less likely to discontinue than
patients with adherence [80% (hazard ratio,
0.437; P\0.0001; 95% confidence interval,
0.212, 0.901). However, after the first
90 days, the results suggest that for patients
taking nbDMARDs at least 20% of the time,
there may be a dose–response effect.
Compared with the patients most adherent
to their nbDMARDs ([80%), the patients with
20% to 39% adherence to their nbDMARD
were 1.3 times more likely to discontinue their
anti-TNF, whereas patients with 40% to 59%
and 60% to 79% nbDMARD adherence were
Table 1 Baseline demographics and clinical characteristics of the study population
Total Pure monotherapy Any combination therapy
Biologic-naive patients, n 7074 1896 5178
Length of follow-up, days (SD) 471.4 (416.4) 332.6 (362.4) 522.3 (423.3)
Age, years (SD) 50.2 (11.9) 48.8 (13.0) 50.8 (11.5)
Male, n (%) 1610 (22.8) 425 (22.4) 1185 (22.9)
Baseline (6-month) non-biologic DMARD, n (%) 5434 (76.8) 804 (42.4) 4630 (89.4)
Patients previously exposed to biologics,a n 2690 844 1846
Length of follow-up, days (SD) 380.8 (348.1) 282.6 (294.4) 425.8 (361.3)
Age, years (SD) 50.2 (11.5) 48.6 (12.2) 50.9 (11.1)
Male, n (%) 506 (18.8) 162 (19.2) 344 (18.6)
Baseline (6-month) non-biologic DMARD, n (%) 1.912 (71.1) 269 (31.9) 1643 (89.0)
DMARD disease-modifying anti-rheumatic drug, SD standard deviation
a Patients with C1 anti-tumor necrosis factor in baseline period. Data are mean (SD) unless otherwise indicated
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1.29 and 1.20 times more likely to discontinue
their anti-TNF, respectively.
DISCUSSION
Previous research has demonstrated enhanced
efficacy of the anti-TNF therapies infliximab,
etanercept, adalimumab, and golimumab when
used in combination with MTX, compared with
using these therapies as monotherapy [10–15].
We examined the prevalence of anti-TNF
monotherapy in a real-world setting and
found that about one-third of patients with RA
receiving anti-TNF therapy received it as pure
monotherapy, which is consistent with
previously published data [16, 17].
Furthermore, even among patients in our
study cohort receiving combination therapy
(anti-TNF ? nbDMARD), one-third had an
nbDMARD adherence rate of\60%, suggesting
that a substantial proportion of this patient
population might not be receiving the full
benefit offered by using the anti-TNF
medications with concomitant nbDMARDs.
Previous estimates of DMARD adherence vary
substantially across studies. In a recent reviews
of the literature [18, 19], the authors found
reported adherence rates that ranged from 22%
to 107%, although there were a variety of study
methods and definitions employed in the
Fig. 2 Distribution of therapy groups by anti-TNF therapy
at a the time of anti-TNF initiation and b during anti-TNF
follow-up in the biologic-naive group, and at c the time of
anti-TNF initiation and d during anti-TNF follow-up in
the biologic-experienced group. ADL adalimumab,
anti-TNF anti-tumor necrosis factor, CZP certolizumab
pegol, ETN etanercept, GOL golimumab, IFX inﬂiximab
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studies reviewed. Additionally, adherence can
change over time, as some patients are
completely non-adherent while others may
have periods of adherence. A study from 1999
found nearly one-quarter of patients with RA
consistently non-adherent [20], whereas in a
more recent study that number was just over
10% [21]. Despite these difficulties, a recent
prospective study that utilized electronic
monitoring of medications (a method thought
to provide some of the most accurate estimates
of adherence) reported that 21% of patients
with RA had an average adherence to DMARDs
of C80% [22], which is noticeably lower than
the 41% to 47% of patients found in our study.
The reasons for non-adherence with
nbDMARDs may be varied. For MTX,
non-adherence has been shown to be
associated with longer disease duration and
low or moderate disease activity [23].
Furthermore, while serious side effects of MTX
are rare [24], patient concerns regarding
potential adverse effects of RA medication may
influence their adherence [25]. A full
understanding of the factors associated with
adherence in patients with RA continues to be
elusive [18]; however, our data do not allow for
further investigation as to the reasons for
non-adherence. One possibility is that patients
use corticosteroids as a replacement for
combination therapy or to compensate for low
adherence. However, in our study, the
proportion of time that patients used
corticosteroids was low (17–22% of days),
suggesting that corticosteroids may have been
used for flare-ups or to treat other conditions.
Persistence is measured as the time from
initiation of therapy to discontinuation of
therapy, which could be a proxy for clinical
effectiveness, tolerability, and patient/provider
preferences. Several studies have demonstrated
better persistence of anti-TNFs when combined
Fig. 3 a Non-biologic disease-modifying anti-rheumatic drug and b methotrexate adherence in patients receiving any
combination
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with nbDMARDs [8, 16, 17, 26–29], but the
impact of adherence with concomitant
nbDMARDs on persistence with the anti-TNF
therapy has not been studied to our knowledge.
In our study, there was a significant association
between nbDMARD adherence and anti-TNF
discontinuation in the period after the first
90 days. During that time period, compared
with the most adherent patients ([80%),
anti-TNF persistence worsened as nbDMARD
adherence decreased. It is likely that the lack of
an association in the first 90 days after starting
the anti-TNF reflected discontinuations due to
primary non-response to the anti-TNF therapy,
which is typically considered to be in the first
12 weeks [30]. One hypothesis is that after the
first 90 days, the difference in persistence may
be linked to differences in the maintenance of
response achieved by those on combination
therapy. MTX co-administration may increase
the bioavailability of anti-TNF therapies and
reduce the development of anti-drug
antibodies, thus prolonging the therapeutic
effect of the anti-TNF [31]. Those with
concomitant therapy with an nbDMARD
typically have lower rates of discontinuation
due to adverse events [8, 26, 28]. One
hypothesis offered to explain this is that
nbDMARDs (MTX specifically) may help
reduce or prevent human anti-chimeric
antibodies known to be induced by anti-TNFs
[8, 26, 32]. This has not been formally tested,
and the literature posing this hypothesis
acknowledges possible confounding due to
unmeasured patient characteristics, such as the
ability to tolerate, and the possibility of partially
responding to, treatment with nbDMARDs.
Although most physicians believe their
patients are compliant with combination
therapy, our review of claims data demonstrate
that this is not occurring in the majority of
patients. Given that there are 53% to 59% of
Fig. 4 Adjusted hazard ratios for discontinuation of index
anti-TNF medication at varying levels of nbDMARD
adherence during anti-TNF treatment period. Anti-TNF
anti-tumor necrosis factor, CI conﬁdence interval,
nbDMARD non-biologic anti-rheumatic disease-modifying
drug
Rheumatol Ther (2015) 2:127–139 135
patients who are prescribed combination
therapy but in fact[80% of the time only use
biologic monotherapy, consideration should be
given to prescribing a biologic that has
demonstrated efficacy when used either as a
monotherapy or in combination with
nbDMARDs. Biologics and other medications
that are effective as monotherapy may expand
the range of treatment options for patients with
RA and warrant further investigation [33].
No consensus exists regarding the level of
medication adherence that is considered
optimal for patients with RA in a real-world
setting, although a systematic review from 2010
concluded that ‘‘most studies show that
adherence is inadequate in many patients’’
[34]. Vermeer et al. reported an adherence of
69% [35] and suggested that perfect adherence
for patients with RA is not realistic due to the
existence of side effects, comorbidities, and the
fact that patients with RA—who frequently
assess their disease severity differently than
does their physician [36]—may be involved in
decisions regarding their treatment. While our
study did not suggest a clear threshold for
adequate adherence with concomitant
nbDMARDs, we did observe an impact on
persistence with anti-TNFs after the initial
90-day period. Patients with \80% adherence
with their nbDMARD had a 1.2 to 1.3 times
higher risk of discontinuing their anti-TNF
therapy compared with patients who had
[80% nbDMARD adherence. The lowest
nbDMARD adherence category (0–19%) was an
exception in this dose–response relationship
and actually demonstrated greater anti-TNF
persistence than the high adherence group.
The reasons for this remain unclear, but one
possible explanation is that this group
represents patients who are more responsive
(i.e., respond well to their anti-TNF therapy)
and therefore do not require concomitant
nbDMARD therapy. This explanation may also
drive the finding that in the first 90 days of
anti-TNF therapy, patients with relatively low
nbDMARD adherence (20–39%) were less likely
to discontinue their anti-TNF medication.
Claims database analysis allows for
estimation of real-world treatment patterns,
and the strength of our analysis derives from
the large, geographically diverse population
studied. All retrospective database analyses are
subject to certain limitations and the results of
this study must be interpreted with appropriate
consideration of these limitations. Claims data
are collected primarily for payment purposes,
not research, and are subject to coding errors.
Additionally, certain information was not
readily available in claims data that could
have had an effect on study outcomes, such as
certain clinical and disease-specific parameters,
which may result in residual confounding due
to factors that were not measured; however, the
analyses adjusted for comorbidity levels and
other characteristics measurable in claims data.
Similarly, claims data do not contain the
rationale for why patients were prescribed
medications, so reasons for patients being
treated with monotherapy versus combination
therapy were unknown. A limitation of this
analysis is that there may be unmeasured
characteristics of some patients that could
influence both adherence with nbDMARDs
and persistence with anti-TNFs. For patients
who have a general tendency to be adherent to
all of their medications (a ‘healthy behavior’
tendency), for example, the association
between adherence and persistence seen in
this study may be in part due to that
unmeasured factor.
We were unable to identify reasons for
non-compliance in claims data. In addition,
because the measures of adherence were based
on a combination of filled prescriptions and
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administrations in medical claims, the lowest
level is driven in part by the nature of filled
prescriptions, which typically are written for a
30-day period; this may partially explain the
lack of effect in the first 90 days after anti-TNF
initiation. Adherence was calculated based on
information about filled prescriptions provided
in claims data and may be overestimated
because it is not known whether patients
consumed the filled prescriptions.
The data used for this study come from a
managed care population; therefore, results of
this analysis are primarily applicable to patients
with RA in managed care settings and may not
be applicable to patients who are uninsured or
covered through Medicaid.
CONCLUSIONS
In conclusion, our results are consistent with
other studies in that we found that almost
one-third of patients with RA receiving
anti-TNF therapy received it as pure
monotherapy. Furthermore, one-third of those
receiving any combination therapy
(anti-TNF ? nbDMARDs) had \60% adherence
to nbDMARDs. Physicians should take this into
consideration when prescribing combination
therapy and may want to consider prescribing
a biologic that is known to be efficacious when
used as a monotherapy or combination with
nbDMARDs. We also found that lack of
adherence with nbDMARDs resulted in poorer
anti-TNF persistence in the period [90 days
after starting the anti-TNF therapy, suggesting
that concomitant nbDMARD use may play a
role in maintenance of response to anti-TNF
therapy. Further research is warranted to assess
the reasons for, and effects of, the observed
lower adherence to concomitant nbDMARDs on
clinical outcomes.
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